openPR Logo
Press release

Global Orphan Drug Designation Status Database Market Clinical Pipeline Trials Insight 2023

10-25-2017 11:02 AM CET | Health & Medicine

Press release from: KuicK Research

Global Orphan Drug Designation Status Database Market Clinical

“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:

• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Global Orphan Drug Market Overview
1.1 Market Overview
1.2 Global Orphan Drug Clinical Pipeline Overview

2. Global Orphan Drug Designation Criteria
2.1 US Food and Drug Administration (US FDA)
2.2 European Medicines Agency (EMA)
2.3 Japan
2.4 Taiwan
2.5 Korean Food and Drug Administration (KFDA)
2.6 Australia

Global Orphan Drug Clinical Pipeline by Company, Indication & Phase

3. Orphan Drug Development Phase: Unknown
3.1 Overview
3.2 Clinical Pipeline Insight

4. Orphan Drug Development Phase: Research
4.1 Overview
4.2 Clinical Pipeline Insight

5. Orphan Drug Development Phase: Preclinical
5.1 Overview
5.2 Clinical Pipeline Insight

6. Orphan Drug Development Phase: Clinical
6.1 Overview
6.2 Clinical Pipeline Insight

7. Orphan Drug Development Phase: Phase-0
7.1 Overview
7.2 Clinical Pipeline Insight

8. Orphan Drug Development Phase: Phase - I
8.1 Overview
8.2 Clinical Pipeline Insight

9. Orphan Drug Development Phase: Phase - I/II
9.1 Overview
9.2 Clinical Pipeline Insight

10. Orphan Drug Development Phase: Phase - II
10.1 Overview
10.2 Clinical Pipeline Insight

11. Orphan Drug Development Phase: Phase - II/III
11.1 Overview
11.2 Clinical Pipeline Insight

12. Orphan Drug Development Phase: Phase - III
12.1 Overview
12.2 Clinical Pipeline Insight

13. Orphan Drug Development Phase: Preregistration
13.1 Overview
13.2 Clinical Pipeline Insight

14. Orphan Drug Development Phase: Registered
14.1 Overview
14.2 Clinical Pipeline Insight

15. Marketed Orphan Drug Clinical Insight by Company, Indication & Phase
15.1 Overview
15.2 Clinical Pipeline Insight

16. Discontinued & Suspended Orphan Drugs in Clinical Pipeline by Company, Indication & Phase
16.1 No Development Reported
16.2 Discontinued
16.3 Preregistration Submission Withdrawal
16.4 Marketed Withdrawal
16.5 Suspended

17. Competitive Landscape
17.1 AOP Orphan
17.2 Agenus
17.3 Alexion
17.4 Bristol Myers Squibb
17.5 Biogen Idec
17.6 Celgene
17.7 Eli Lilly
17.8 Genethon
17.9 Genzyme Corporation
17.10 Glaxosmithkline
17.11 Merck
17.12 Novartis Pharmaceuticals
17.13 Orphan Europe
17.14 Pfizer
17.15 Prosensa
17.16 Rare Disease Therapeutics
17.17 Roche
17.18 Sanofi
17.19 Shire
17.20 Teva Pharmaceutical

For Report Sample Contact: neeraj@kuickresearch.co or +91-11-47067990

Figure 1-1: Global Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-2: US - Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-3: Europe - Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-4: Asia* - Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-5: Global - Orphan Drug Clinical Pipeline by Phase (%), 2016 till 2023
Figure 1-6: Global - Orphan Drug Clinical Pipeline by Phase (Numbers), 2016 till 2023
Figure 1-7: Global - Orphan Drug Clinical Pipeline by Phase (%), 2016 till 2023
Figure 1-8: Global - Orphan Drug Clinical Pipeline by Phase (Numbers), 2016 till 2023
Figure 17-1: AOP Orphan
Figure 17-2: Agenus Pipeline
Figure 17-3: Genethon Drug Pipeline
Figure 17-4: Genzyme Drug Pipeline
Figure 17-5: Orphan Europe Pipeline
Figure 17-6: Prosensa Drug Pipeline
Figure 17-7: Shire Drug Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Orphan Drug Designation Status Database Market Clinical Pipeline Trials Insight 2023 here

News-ID: 784825 • Views: 251

More Releases from KuicK Research

Stem Cell Therapy Revolutionizing Conventional Therapy Market
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
Cell Therapy to Transform Immuno Oncology Landscape
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025
"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights: US Breast Cancer Drug Market Opportunity: US$ 20 Billion US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment US Breast Cancer Marketed Drugs: 42 Drugs US Breast Cancer Drug Clinical Pipeline: 317 Drugs Dosage and Pricing Insight for Preventive and Treatment Drugs US Breast Cancer Drug Market Dynamics For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report:
Download Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportun …
"Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportunity Insight 2026" Report Highlights: Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 Cell Therapy Clinical Trial Insight by Indication, Company and Country Global Cell Therapy Clinical Pipeline: 767 Cell Therapies Globally Marketed Cell Therapies: 25 Cell Therapies Maximum Number of Marketed Cell Therapies In USA: 15 Therapies Price and Product Insight By Region/Country Regional Analysis of the Cell Therapy Market

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning